Silvia Buonamici

Silvia Buonamici led the discovery and development of H3B-8800, the first oral spliceosome modulator to enter clinical trials for splicing factor-mutant myeloid malignancies, representing a breakthrough in targeting cancer-specific RNA splicing defects. Her work demonstrated that H3B-8800 preferentially kills splicing factor-mutant cells by exploiting their heightened sensitivity to further splicing perturbation. She established the therapeutic window for spliceosome modulation in cancer. Her translational research has opened a new class of RNA-targeted cancer therapeutics.